Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Ritonavir and ASP2151 in Healthy Men
NCT02223351Phase 1Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Amenamevir in herpes simplex virus infection and herpes zoster (HZ) (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Peak Plasma Concentration of ASP2151 at 72 hours, Time of Peak Concentration of ASP2151 at 72 hours and 4 more. Started Sep 2014; status: completed.
02
Drugs
Amenamevir
03
Conditions
herpes simplex virus infectionherpes zoster (HZ)
Beyond the preview
Go deeper on NCT02223351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223351.